GlassScriptPhysician profile
John P Delirio
NPI 1508341751
$1,499.62
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,203 · 2022: $296.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $880.88 | 2021 | |
| Collegium Pharmaceutical, INC. | $215.86 | 2021 | |
| Abbvie INC. | $100.72 | 2022 | |
| Amgen INC. | $60.23 | 2021-2022 | |
| Lundbeck LLC | $57.38 | 2022 | |
| Horizon Therapeutics Plc | $48.74 | 2022 | |
| Forte Bio-Pharma LLC | $28.39 | 2021 | |
| Redhill Biopharma INC. | $27.65 | 2021 | |
| Lilly USA, LLC | $23.48 | 2022 | |
| Almatica Pharma LLC | $21.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.11 | 2022 | |
| Nevro Corp. | $14.48 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Delirio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.